probucol has been researched along with Inflammation in 19 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have investigated the possible effects and mechanism of atorvastatin, a statin, and/or probucol, a powerful antioxidant used to lower cholesterol before 1995, on the atherosclerosis development." | 7.91 | Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice. ( Guo, X; Li, X; Wang, L; Wang, P; Xia, X, 2019) |
| "The effect of the lipid-lowering agent probucol in inflammatory hyperalgesia and leukocyte recruitment was evaluated in a model of subacute inflammation by Complete Freund's adjuvant (CFA)." | 7.91 | Probucol Ameliorates Complete Freund's Adjuvant-Induced Hyperalgesia by Targeting Peripheral and Spinal Cord Inflammation. ( Badaro-Garcia, S; Borghi, SM; Camilios-Neto, D; Casagrande, R; Dos Santos, TS; Fattori, V; Manchope, MF; Verri, WA; Zucoloto, AZ, 2019) |
| "To enhance the bioavailability and brain uptake of probucol and examine whether it attenuates neuroinflammation and neurodegeneration by utilizing a sodium alginate nanoencapsulation technique." | 7.88 | Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. ( Al-Salami, H; Brook, E; D'Alonzo, Z; Fimognari, N; Graneri, L; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Stephenson, A; Takechi, R, 2018) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 7.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| "Probucol has been shown to prevent cerebral capillary disturbances characterized by blood-to-brain extravasation of plasma derived proteins and neurovascular inflammation in mice maintained on western-styled diets for 12 weeks." | 7.80 | Long-term probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction. ( Giles, C; Lam, V; Mamo, JC; Pallebage-Gamarallage, MM; Takechi, R, 2014) |
| "In this model, stent-based delivery of 1% succinobucol using a polymer-free stent platform increased neointimal formation and inflammation following coronary stenting." | 7.79 | Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model. ( Agbani, EO; Behnisch, B; Czudaj, P; Kennedy, S; McCormick, C; McPhaden, A; Mullen, A; Oldroyd, KG; Wadsworth, RM; Watt, J, 2013) |
| " We examined whether antioxidant and antiinflammatory treatment with probucol decreases myocardial oxidative stress and inflammation and attenuates the progression of left ventricular (LV) dysfunction and remodeling (dilatation) in tachycardia-induced HF." | 7.71 | Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. ( Egashira, K; Hayashidani, S; Machida, Y; Nakamura, R; Takeshita, A; Takeya, M; Tsutsui, H; Utsumi, H, 2002) |
| "Probucol (PB) is a lipophilic drug with potential applications in type 2 diabetes (T2D)." | 5.43 | Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line. ( Al-Salami, H; Arfuso, F; Mooranian, A; Negrulj, R, 2016) |
| "We have investigated the possible effects and mechanism of atorvastatin, a statin, and/or probucol, a powerful antioxidant used to lower cholesterol before 1995, on the atherosclerosis development." | 3.91 | Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice. ( Guo, X; Li, X; Wang, L; Wang, P; Xia, X, 2019) |
| "The effect of the lipid-lowering agent probucol in inflammatory hyperalgesia and leukocyte recruitment was evaluated in a model of subacute inflammation by Complete Freund's adjuvant (CFA)." | 3.91 | Probucol Ameliorates Complete Freund's Adjuvant-Induced Hyperalgesia by Targeting Peripheral and Spinal Cord Inflammation. ( Badaro-Garcia, S; Borghi, SM; Camilios-Neto, D; Casagrande, R; Dos Santos, TS; Fattori, V; Manchope, MF; Verri, WA; Zucoloto, AZ, 2019) |
| "To enhance the bioavailability and brain uptake of probucol and examine whether it attenuates neuroinflammation and neurodegeneration by utilizing a sodium alginate nanoencapsulation technique." | 3.88 | Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. ( Al-Salami, H; Brook, E; D'Alonzo, Z; Fimognari, N; Graneri, L; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Stephenson, A; Takechi, R, 2018) |
| "We have shown that probucol-induced HDL deficiency impairs the ability of established lesions to regress in response to reversal of the genetic hypercholesterolemia in Apoe knockout mice." | 3.88 | HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution. ( Hoekstra, M; Lendvai, Z; van der Sluis, RJ; Van Eck, M; Verwilligen, RAF; Wever, R, 2018) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 3.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| "Probucol has been shown to prevent cerebral capillary disturbances characterized by blood-to-brain extravasation of plasma derived proteins and neurovascular inflammation in mice maintained on western-styled diets for 12 weeks." | 3.80 | Long-term probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction. ( Giles, C; Lam, V; Mamo, JC; Pallebage-Gamarallage, MM; Takechi, R, 2014) |
| "In this model, stent-based delivery of 1% succinobucol using a polymer-free stent platform increased neointimal formation and inflammation following coronary stenting." | 3.79 | Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model. ( Agbani, EO; Behnisch, B; Czudaj, P; Kennedy, S; McCormick, C; McPhaden, A; Mullen, A; Oldroyd, KG; Wadsworth, RM; Watt, J, 2013) |
| " We examined whether antioxidant and antiinflammatory treatment with probucol decreases myocardial oxidative stress and inflammation and attenuates the progression of left ventricular (LV) dysfunction and remodeling (dilatation) in tachycardia-induced HF." | 3.71 | Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. ( Egashira, K; Hayashidani, S; Machida, Y; Nakamura, R; Takeshita, A; Takeya, M; Tsutsui, H; Utsumi, H, 2002) |
| "Probucol (PB) is a lipophilic drug with potential applications in type 2 diabetes (T2D)." | 1.43 | Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line. ( Al-Salami, H; Arfuso, F; Mooranian, A; Negrulj, R, 2016) |
| "Probucol is a lipid-lowering agent with potent anti-oxidant properties once commonly used for the treatment of cardiovascular disease." | 1.39 | Probucol prevents blood-brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding. ( Dhaliwal, SS; Galloway, S; Lam, V; Mamo, JC; Pallebage-Gamarallage, MM; Takechi, R, 2013) |
| " Previous results suggest that vascular dysfunction in OZR is associated with chronic reduction in vascular nitric-oxide (NO) bioavailability and chronic inflammation, both frequently associated with hypercholesterolemia." | 1.35 | Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. ( Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meng, CQ | 1 |
| Somers, PK | 1 |
| Hoong, LK | 1 |
| Zheng, XS | 1 |
| Ye, Z | 1 |
| Worsencroft, KJ | 1 |
| Simpson, JE | 1 |
| Hotema, MR | 1 |
| Weingarten, MD | 1 |
| MacDOnald, ML | 1 |
| Hill, RR | 1 |
| Marino, EM | 1 |
| Suen, KL | 1 |
| Luchoomun, J | 1 |
| Kunsch, C | 1 |
| Landers, LK | 1 |
| Stefanopoulos, D | 1 |
| Howard, RB | 1 |
| Sundell, CL | 1 |
| Saxena, U | 1 |
| Wasserman, MA | 1 |
| Sikorski, JA | 1 |
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Zucoloto, AZ | 2 |
| Manchope, MF | 2 |
| Staurengo-Ferrari, L | 1 |
| Pinho-Ribeiro, FA | 1 |
| Zarpelon, AC | 1 |
| Saraiva, ALL | 1 |
| Cecílio, NT | 1 |
| Alves-Filho, JC | 1 |
| Cunha, TM | 1 |
| Menezes, GB | 1 |
| Cunha, FQ | 1 |
| Casagrande, R | 2 |
| Verri, WA | 2 |
| Guo, X | 3 |
| Liao, J | 1 |
| Huang, X | 1 |
| Wang, Y | 2 |
| Huang, W | 1 |
| Liu, G | 1 |
| Zhang, M | 1 |
| Hou, Y | 1 |
| Shen, Y | 1 |
| Shang, D | 1 |
| Zhang, D | 1 |
| Mamo, JC | 3 |
| Lam, V | 3 |
| Al-Salami, H | 2 |
| Brook, E | 1 |
| Mooranian, A | 2 |
| Nesbit, M | 1 |
| Graneri, L | 1 |
| D'Alonzo, Z | 1 |
| Fimognari, N | 1 |
| Stephenson, A | 1 |
| Takechi, R | 3 |
| van der Sluis, RJ | 1 |
| Verwilligen, RAF | 1 |
| Lendvai, Z | 1 |
| Wever, R | 1 |
| Hoekstra, M | 1 |
| Van Eck, M | 1 |
| Wang, L | 1 |
| Xia, X | 1 |
| Wang, P | 1 |
| Li, X | 1 |
| Borghi, SM | 1 |
| Dos Santos, TS | 1 |
| Fattori, V | 1 |
| Badaro-Garcia, S | 1 |
| Camilios-Neto, D | 1 |
| Pallebage-Gamarallage, MM | 2 |
| Giles, C | 1 |
| Zhu, WB | 1 |
| Wang, YH | 1 |
| Sun, GF | 1 |
| Wu, JH | 1 |
| Bai, L | 1 |
| Lin, Y | 1 |
| Chen, Y | 1 |
| Guan, H | 1 |
| Zhu, N | 1 |
| Li, Y | 1 |
| Gao, S | 1 |
| Sun, L | 1 |
| Zhao, S | 1 |
| Fan, J | 1 |
| Liu, E | 1 |
| Negrulj, R | 1 |
| Arfuso, F | 1 |
| Goodwill, AG | 1 |
| Frisbee, SJ | 1 |
| Stapleton, PA | 1 |
| James, ME | 1 |
| Frisbee, JC | 1 |
| Li, T | 1 |
| Chen, W | 1 |
| An, F | 1 |
| Tian, H | 1 |
| Zhang, J | 1 |
| Peng, J | 1 |
| Zhang, Y | 1 |
| Guo, Y | 1 |
| Watt, J | 1 |
| Kennedy, S | 1 |
| McCormick, C | 1 |
| Agbani, EO | 1 |
| McPhaden, A | 1 |
| Mullen, A | 1 |
| Czudaj, P | 1 |
| Behnisch, B | 1 |
| Wadsworth, RM | 1 |
| Oldroyd, KG | 1 |
| Galloway, S | 1 |
| Dhaliwal, SS | 1 |
| Nakamura, R | 1 |
| Egashira, K | 1 |
| Machida, Y | 1 |
| Hayashidani, S | 1 |
| Takeya, M | 1 |
| Utsumi, H | 1 |
| Tsutsui, H | 1 |
| Takeshita, A | 1 |
| Ransom, J | 1 |
19 other studies available for probucol and Inflammation
| Article | Year |
|---|---|
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antioxidants; Cells, Cul | 2004 |
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Probucol attenuates lipopolysaccharide-induced leukocyte recruitment and inflammatory hyperalgesia: effect on NF-кB activation and cytokine production.
Topics: Animals; Cytokines; Hyperalgesia; Inflammation; Leukocytes; Lipopolysaccharides; Macrophages; Male; | 2017 |
Reversal of adipose tissue loss by probucol in mice with deficiency of both scavenger receptor class B type 1 and LDL receptor on high fat diet.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Antioxidants; Apoptosis; Diet, High-Fat; Endoplas | 2018 |
Probucol reverses homocysteine induced inflammatory monocytes differentiation and oxidative stress.
Topics: Animals; Cell Differentiation; Homocysteine; Inflammation; Male; Mice; Monocytes; Oxidative Stress; | 2018 |
Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration.
Topics: Alginates; Animals; Biological Availability; Blood-Brain Barrier; Capsules; Diet, High-Fat; Disease | 2018 |
HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Bone Marrow; Bone Marrow Transplantation; Cholesterol, | 2018 |
Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
Topics: Animals; Antioxidants; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol; Cytokines; Die | 2019 |
Probucol Ameliorates Complete Freund's Adjuvant-Induced Hyperalgesia by Targeting Peripheral and Spinal Cord Inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Freund's Adjuvant; Hyperalgesia; Inflammation; Mice | 2019 |
Long-term probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction.
Topics: Animals; Apolipoproteins B; Blood-Brain Barrier; Capillaries; Diet, Fat-Restricted; Female; Immunogl | 2014 |
Protective effect and mechanism of probucol in the treatment of spinal cord injury.
Topics: Animals; Blotting, Western; Cytokines; Female; Inflammation; Inflammation Mediators; Malondialdehyde | 2015 |
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hy | 2015 |
Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line.
Topics: Animals; Capsules; Cell Line; Cell Survival; Diabetes Mellitus, Type 2; Drug Delivery Systems; Infla | 2016 |
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids | 2009 |
Probucol attenuates inflammation and increases stability of vulnerable atherosclerotic plaques in rabbits.
Topics: Animals; Aorta, Abdominal; Biomarkers; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Gene Expre | 2011 |
Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model.
Topics: Animals; Cardiovascular Agents; Cattle; Cell Survival; Cells, Cultured; Coronary Vessels; Dose-Respo | 2013 |
Probucol prevents blood-brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding.
Topics: Amyloid beta-Peptides; Animals; Apolipoproteins B; Blood-Brain Barrier; Cerebrovascular Disorders; C | 2013 |
Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated | 2002 |
Are small biotechs still underselling themselves?
Topics: Biotechnology; Capital Financing; Drug Industry; Heart; Humans; Inflammation; Investments; Marketing | 2006 |